Journal Mobile Options
Table of Contents
Vol. 72, No. 2, 2011
Issue release date: September 2011
Section title: Original Article
Gynecol Obstet Invest 2011;72:103–108
(DOI:10.1159/000323828)

Clinical Characteristics and Type of Thrombophilia in Women with Pregnancy-Related Venous Thromboembolic Disease

Mitic G.a · Kovac M.c · Jurisic D.a · Djordjevic V.d · Ilic V.e · Salatic I.a · Spasic D.b · Novakov Mikic A.a
aClinical Center of Vojvodina and bDepartment of Mechanics, University of Novi Sad, Novi Sad, and cNational Blood Transfusion Institute, dInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade and eInstitute of Medical Research, Military Medical Academy, Belgrade, Serbia

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: 9/7/2010
Accepted: 12/14/2010
Published online: 5/24/2011
Issue release date: September 2011

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 3

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI

Abstract

Background: Normal pregnancy is characterized by numerous changes in the hemostatic system, creating the hypercoagulable state which increases the risk of venous thromboembolic event (VTE) occurrence. The risk is further increased by the presence of inherited or acquired thrombophilia. Objective: In this study, we aimed to determine the prevalence of different types of thrombophilia in women with pregnancy-related VTE, and to investigate the possible connection between the type of thrombophilia and localization of VTE as well as the gestational age of VTE occurrence. Participants and Methods: Two hundred and two women with the first episode of pregnancy-related VTE and 130 controls were investigated. The antithrombin, protein C and protein S activity, APC resistance, FVG1691A, and FIIG20210A were determined. None of the investigated women was pregnant at the time of thrombophilia testing, and none was using oral contraceptives. Results: Thrombophilia was diagnosed in 95 patients (47%) and 7 controls (5.4%). The prevalence of FV Leiden, FIIG20210A mutations, antithrombin, PC and PS deficiencies taken together and combined thrombophilia was 22.3, 10.4, 6.9 and 6.9%, respectively. Significantly more frequent antepartum occurrence of VTE (11 vs. 3, p < 0.05) was found in women with natural coagulation inhibitor deficiency. Pulmonary embolism occurred more frequently in nonthrombophilic women (25 vs. 3, p < 0.001). Conclusion: Inherited thrombophilia was found to be considerably more frequently present in women with pregnancy- and puerperium-related VTE compared to healthy controls. Women with thrombophilia are at higher risk of developing thromboses localized in the iliacofemoral region, and women without thrombophilia are at higher risk of developing pulmonary embolism. Deficiency in natural coagulation inhibitors is associated with antepartum VTE occurrence.

© 2011 S. Karger AG, Basel


  

Author Contacts

Gorana Mitic
Thrombosis and Haemostasis Unit, Institute of Laboratory Diagnostics
Clinical Center of Vojvodina, 1 Hajduk Veljka st.
RS–21000 Novi Sad (Serbia)
Tel. +381 21 484 3122, E-Mail miticgns@yahoo.com

  

Article Information

Received: September 7, 2010
Accepted after revision: December 14, 2010
Published online: May 24, 2011
Number of Print Pages : 6
Number of Figures : 1, Number of Tables : 3, Number of References : 22

  

Publication Details

Gynecologic and Obstetric Investigation

Vol. 72, No. 2, Year 2011 (Cover Date: September 2011)

Journal Editor: D'Hooghe T.M. (Leuven)
ISSN: 0378-7346 (Print), eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI


Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: 9/7/2010
Accepted: 12/14/2010
Published online: 5/24/2011
Issue release date: September 2011

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 3

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.